JPMorgan Chase & Co. Issues Pessimistic Forecast for Agilent Technologies (NYSE:A) Stock Price

Agilent Technologies (NYSE:A) had its price target cut by equities research analysts at JPMorgan Chase & Co. from $165.00 to $160.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 24.47% from the stock’s current price.

Other equities analysts have also issued reports about the stock. Bank of America lifted their target price on shares of Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a report on Thursday, August 22nd. Barclays lifted their price objective on Agilent Technologies from $135.00 to $145.00 and gave the company an “underweight” rating in a research note on Tuesday, October 15th. UBS Group lifted their price target on Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a research report on Thursday, August 22nd. Citigroup boosted their price target on Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Finally, Evercore ISI raised their price objective on shares of Agilent Technologies from $135.00 to $145.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $144.71.

Agilent Technologies Stock Down 4.4 %

NYSE:A opened at $128.54 on Tuesday. Agilent Technologies has a 1-year low of $124.10 and a 1-year high of $155.35. The company has a market capitalization of $36.93 billion, a PE ratio of 27.18, a P/E/G ratio of 5.89 and a beta of 1.07. The firm’s 50-day moving average price is $137.82 and its 200-day moving average price is $137.54. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.78 and a quick ratio of 1.37.

Insider Buying and Selling at Agilent Technologies

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the business’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the transaction, the senior vice president now owns 40,011 shares in the company, valued at $5,801,595. The trade was a 19.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Hedge Funds Weigh In On Agilent Technologies

A number of large investors have recently made changes to their positions in the company. Menard Financial Group LLC lifted its stake in Agilent Technologies by 1.6% in the second quarter. Menard Financial Group LLC now owns 4,845 shares of the medical research company’s stock worth $628,000 after purchasing an additional 77 shares during the last quarter. McAdam LLC lifted its stake in shares of Agilent Technologies by 3.1% during the 3rd quarter. McAdam LLC now owns 2,531 shares of the medical research company’s stock worth $376,000 after acquiring an additional 77 shares during the last quarter. Brown Brothers Harriman & Co. boosted its holdings in Agilent Technologies by 13.5% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock valued at $96,000 after acquiring an additional 77 shares during the period. Global Retirement Partners LLC grew its position in Agilent Technologies by 3.2% in the 3rd quarter. Global Retirement Partners LLC now owns 2,570 shares of the medical research company’s stock valued at $382,000 after acquiring an additional 79 shares during the last quarter. Finally, Rovin Capital UT ADV increased its stake in Agilent Technologies by 1.6% in the third quarter. Rovin Capital UT ADV now owns 5,049 shares of the medical research company’s stock worth $750,000 after purchasing an additional 81 shares during the period.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.